<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172117</url>
  </required_header>
  <id_info>
    <org_study_id>MP-CR-010-F/U</org_study_id>
    <nct_id>NCT03172117</nct_id>
  </id_info>
  <brief_title>Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.</brief_title>
  <official_title>Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medipost Co Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medipost Co Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A long-term follow-up study to obtain safety and efficacy data in subjects who completed
      phase 1/2a clinical trial of NEUROSTEM® (NCT02054208), comparing NEUROSTEM and placebo groups
      for up to 36 months after the initial administration in patients suffering from Alzheimer's
      disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subjects will be followed up at 12-month, 24-month, and 36-month (phone call) after the
      initial administration of NEUROSTEM®.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from the baseline in ADAS-Cog</measure>
    <time_frame>24 month after the first dose</time_frame>
    <description>Alzheimer's Disease assessment Scale-Cognitive Subscale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline in S-IADL</measure>
    <time_frame>24 month after the first dose</time_frame>
    <description>Seoul Instrumental Activities of Daily Living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline in K-MMSE</measure>
    <time_frame>24 month after the first dose</time_frame>
    <description>Mini Mental State Exmination Korean version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline in CGA-NPI</measure>
    <time_frame>24 month after the first dose</time_frame>
    <description>Caregiver-administered Neuropsychiatric Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADAS-Cog Response Rate</measure>
    <time_frame>24 month after the first dose</time_frame>
    <description>the ADAS-cog score at 24 month after the first administration compared to the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CDR-SOB</measure>
    <time_frame>24 month after the first dose</time_frame>
    <description>Clinical Dementia Rating-Sum of Box</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CIBIC-plus</measure>
    <time_frame>24 month after the first dose</time_frame>
    <description>The Clinician's Interview Based Impression of Change-plus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Florbetaben-PET</measure>
    <time_frame>24 month after the first dose</time_frame>
    <description>Florbetaben - Pittsburgh Compound B-positron emission tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FDG-PET (CMRglc: regional cerebral metabolic rate for glucose)</measure>
    <time_frame>24 month after the first dose</time_frame>
    <description>fluorodeoxyglucose positron emission tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in MRI (DTI mapping)</measure>
    <time_frame>24 month after the first dose</time_frame>
    <description>MRI Analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline in CSF biomarkers</measure>
    <time_frame>24 month after the first dose</time_frame>
    <description>biomakrer analysis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>NEUROSTEM® (hUCB-MSCs)- low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NEUROSTEM® (hUCB-MSCs) - high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline 2mL, doses separated by 4 weeks for a total of 3 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human umbilical cord blood derived mesenchymal stem cells</intervention_name>
    <description>Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
High dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals</description>
    <arm_group_label>NEUROSTEM® (hUCB-MSCs)- low dose</arm_group_label>
    <arm_group_label>NEUROSTEM® (hUCB-MSCs) - high dose</arm_group_label>
    <other_name>NEUROSTEM®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline 2mL</intervention_name>
    <description>Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Assessment of safety and exploratory treatment efficacy in subjects who were enrolled
             and completed phase 1/2a clinical trial of NEUROSTEM®.

          -  Subjects who have been treated with either NEUROSTEM® or placebo at least 12 months
             ago.

          -  Subjects who voluntarily decided to participate and signed the consent form after
             receiving explanations on the clinical trial (in case it is difficult for the
             participant to sign, the consent of the legal representative)

        Exclusion Criteria:

          -  Subjects who were not enrolled in phase 1/2a clinical trial of Neurostem® for
             assessing safety and exploratory treatment efficacy

          -  Other subjects, excluding those listed above, who were deemed unsuitable by the PI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>86 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sujin Choi, MD</last_name>
    <phone>+82-2-3465-6770</phone>
    <email>sjchoi@medi-post.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heejin Choi, MD</last_name>
      <phone>+82-2-3410-1947</phone>
      <email>evekhj@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Duk L Na, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2017</study_first_submitted>
  <study_first_submitted_qc>May 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>May 29, 2017</last_update_submitted>
  <last_update_submitted_qc>May 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

